Access count of this item: 116

Files in This Item:
File Description SizeFormat 
38_305.pdf376.47 kBAdobe PDFView/Open
Title: Sodium-4-〔2-{2,3-dimethyl-4-〔1-(4-isobutylphenyl)ethoxy〕benzoylamino}phenoxy〕butyrate (ONO-3805)のラット副性器への効果
Other Titles: The effect of sodium-4-[2-(2,3-dimethyl-4-[1-(4- isobutylphenyl)ethoxy]benzolamino)phenoxy] butyrate (ONO-3805) and antiandrogenic agents on the rat accessory sex organs
Authors: 高橋, 修  KAKEN_name
今井, 強一  KAKEN_name
渡辺, 恵子  KAKEN_name
中沢, 康夫  KAKEN_name
中田, 誠司  KAKEN_name
栗田, 誠  KAKEN_name
斉藤, 佳隆  KAKEN_name
久保田, 裕  KAKEN_name
山中, 英寿  KAKEN_name
Author's alias: Takahashi, Osamu
Imai, Kyoichi
Watanabe, Keiko
Nakazawa, Yasuo
Nakata, Seizi
Kurita, Makoto
Saito, Yoshitaka
Kubota, Hiroshi
Yamanaka, Hidetoshi
Keywords: 5a-reductase inhibitor
Accessory sex organ
Issue Date: Mar-1992
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 38
Issue: 3
Start page: 305
End page: 310
Abstract: 新たに開発された非ステロイド系5α-reductase阻害剤,ONO-3805のラット副性器への効果をchlormadione acetate (CMA)および非ステロイド系抗アンドロゲン剤flutamide (FLU)のそれと比較した.ONO-3805は副性器重量低下についてCMAと同等の効果を示した.さらに,本剤は血清テストステロン・レベルに影響を与えることはなかったが,CMAおよびFLUはこれを有意に変動させた
The effects of sodium-4-[2-(2,3-dimethyl-4-[1-(4-isobutylphenyl) ethoxy]benzolamino)phenoxy]butyrate (ONO-3805), newly developed as a non-steroidal 5 alpha-reductase inhibitor, on rat accessory sex organs was compared with chlormadinone acetate (CMA) and non-steroidal antiandrogen, flutamide (FLU). ONO-3805 demonstrated excellent antiandrogenic activity which was similar to that of CMA in reducing the accessory sex organ weight. Moreover this agent did not show any significant effects on the serum testosterone level, but CMA and FLU changed it significantly. We previously reported the androgenic activity of antiandrogen (CMA, FLU, AA560, cyproterone acetate, medroxy progesterone, estrogen), but ONO-3805 is free of androgenic activity.
PubMed ID: 1381863
Appears in Collections:Vol.38 No.3

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.